Table 3. Effectiveness of qHPV vaccination in women 24 to 45 years of age against HPV 31/33/35/39/45/51/52/56/58/59-related CIN or condyloma (cumulative incidence, day 1 to year 6 in the EVG FAS population).
Early Vaccination Group (N = 1,910) | |||||
Endpoint | n | Cases | PYR | Rate | 95% CI |
HPV 31/33/35/39/45/51/52/56/58/59-Related CIN or Condyloma | 1,910 | 93 | 8,403.7 | 1.1 | (0.9, 1.4) |
By HPV Type | |||||
HPV 31-Related CIN or Condyloma | 1,910 | 16 | 8,678.1 | 0.2 | (0.1, 0.3) |
HPV 33-Related CIN or Condyloma | 1,910 | 7 | 8,711.7 | 0.1 | (0.0, 0.2) |
HPV 35-Related CIN or Condyloma | 1,910 | 4 | 8,717.4 | 0.0 | (0.0, 0.1) |
HPV 39-Related CIN or Condyloma | 1,910 | 17 | 8,668.3 | 0.2 | (0.1, 0.3) |
HPV 45-Related CIN or Condyloma | 1,910 | 5 | 8,720.4 | 0.1 | (0.0, 0.1) |
HPV 51-Related CIN or Condyloma | 1,910 | 17 | 8,686.5 | 0.2 | (0.1, 0.3) |
HPV 52-Related CIN or Condyloma | 1,910 | 13 | 8,698.5 | 0.1 | (0.1, 0.3) |
HPV 56-Related CIN or Condyloma | 1,910 | 23 | 8,654.5 | 0.3 | (0.2, 0.4) |
HPV 58-Related CIN or Condyloma | 1,910 | 17 | 8,664.4 | 0.2 | (0.1, 0.3) |
HPV 59-Related CIN or Condyloma | 1,910 | 6 | 8,712.4 | 0.1 | (0.0, 0.1) |
HPV 31/33/35/39/45/51/52/56/58/59-Related CIN or Condyloma | 1,910 | 93 | 8,403.7 | 1.1 | (0.9, 1.4) |
By Endpoint Type | |||||
CIN (any grade) | 1,909 | 93 | 8,191.1 | 1.1 | (0.9, 1.4) |
CIN 1 | 1,909 | 72 | 8,210.3 | 0.9 | (0.7, 1.1) |
CIN 2 or worse | 1,909 | 40 | 8,296.4 | 0.5 | (0.3, 0.7) |
CIN 2 | 1,909 | 28 | 8,302.2 | 0.3 | (0.2, 0.5) |
CIN 3 | 1,909 | 23 | 8,311.0 | 0.3 | (0.2, 0.4) |
AIS | 1,909 | 0 | 8,319.2 | 0.0 | (0.0, 0.0) |
Cervical Cancer | 1,909 | 0 | 8,319.2 | 0.0 | (0.0, 0.0) |
Condyloma | 1,910 | 0 | 8,721.0 | 0.0 | (0.0, 0.0) |
N = Number of subjects in the indicated group who received at least 1 dose of the qHPV vaccine.
n = Number of subjects in the indicated analysis population.
PYR = person years at risk; Rate = rate per 100 person years at risk; AIS = Adenocarcinoma in situ; CI = Confidence interval; CIN = Cervical intraepithelial neoplasia; HPV = Human papillomavirus; qHPV = Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine.